2020
Empagliflozin in Heart Failure
Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, Riello R, Bellumkonda L, Cox Z, Collins S, Jeon S, Turner JM, Wilson FP, Butler J, Inzucchi SE, Testani JM. Empagliflozin in Heart Failure. Circulation 2020, 142: 1028-1039. PMID: 32410463, PMCID: PMC7521417, DOI: 10.1161/circulationaha.120.045691.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsCotransporter 2 inhibitorsNeurohormonal activationHeart failureRenal dysfunctionBlood volumeHeart failure-related outcomesPlacebo-controlled crossover studyType 2 diabetes mellitusProximal tubular siteHeart failure outcomesStable heart failureUrinary glucose excretionUric acid levelsElectrolyte wastingEmpagliflozin monotherapyOral empagliflozinPlacebo periodStudy drugGlucose excretionNatriuretic effectPotassium wastingTubular sitesDiabetes mellitusFractional excretion
2011
Prognostic Importance of Early Worsening Renal Function After Initiation of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Cardiac Dysfunction
Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic Importance of Early Worsening Renal Function After Initiation of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Cardiac Dysfunction. Circulation Heart Failure 2011, 4: 685-691. PMID: 21903907, PMCID: PMC3248247, DOI: 10.1161/circheartfailure.111.963256.Peer-Reviewed Original ResearchConceptsGlomerular filtration rateRenal functionPrognostic significanceAngiotensin-Converting Enzyme Inhibitor TherapyACE-I therapySetting of angiotensinWorsening Renal FunctionEnzyme inhibitor therapyPrimary end pointAdverse prognostic significanceEnalapril groupEnalapril therapyPlacebo groupStudy drugVentricular dysfunctionHeart failureInhibitor therapyCardiac dysfunctionPrognostic importanceFiltration rateSurvival advantageMortality rateOverall populationEnd pointTherapy